Cargando…
Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis
Obeticholic acid (OCA) is approved for the treatment of patients with primary biliary cholangitis (PBC) who are partial responders or intolerant to ursodeoxycholic acid. Reports of serious liver injury have raised concerns about its safety in cirrhosis. We investigated the effects of treatment with...
Autores principales: | John, Binu V., Schwartz, Kaley, Levy, Cynthia, Dahman, Bassam, Deng, Yangyang, Martin, Paul, Taddei, Tamar H., Kaplan, David E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369937/ https://www.ncbi.nlm.nih.gov/pubmed/34430786 http://dx.doi.org/10.1002/hep4.1720 |
Ejemplares similares
-
Obeticholic acid for primary biliary cholangitis
Publicado: (2020) -
Obeticholic Acid for Primary Biliary Cholangitis
por: Floreani, Annarosa, et al.
Publicado: (2022) -
Real‐World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis
por: Roberts, Surain B., et al.
Publicado: (2020) -
782: COMPARISON OF INFECTION-INDUCED AND VACCINE-INDUCED IMMUNITY AGAINST CORONAVIRUS 2019 IN PATIENTS WITH CIRRHOSIS
por: John, Binu V., et al.
Publicado: (2022) -
New developments in the treatment of primary biliary cholangitis – role of obeticholic acid
por: Jhaveri, Manan A, et al.
Publicado: (2017)